Experiments have demonstrated that Panax notoginseng can effectively reduce myocardial fibrosis, IL-6, albumin, AKT1, TNF and vascular endothelial growth factor A (VEGFA) are the five most critical action targets, and the advanced glycosylation end-product-advanced glycosylation end-product receptor (AGE-RAGE) signaling pathway is the most important potential pathway for Panax notoginseng to treat myocardial fibrosis in diabetic complications (55). Here, VEGFA is linked to Myocardial fibrosis.